Today's Daily Dose brings you news about the FDA approval of Crescita's enhanced formulation of Pliaglis; failure of Supernus' phase III trial of SPN-810 for the treatment of Impulsive Aggression (IA) in ADHD; NextCure's promising data from phase I portion of its ongoing phase I/II trial of NC318 in advanced or metastatic solid tumors; quarterly financial results of Portola, and KORU Medical.
from RTT - Biotech https://ift.tt/2NIq5m9
via IFTTT
No comments:
Post a Comment